Historical Valuation
Axsome Therapeutics Inc (AXSM) is now in the Overvalued zone, suggesting that its current forward PS ratio of 10.38 is considered Overvalued compared with the five-year average of -23.39. The fair price of Axsome Therapeutics Inc (AXSM) is between 127.42 to 151.75 according to relative valuation methord. Compared to the current price of 167.55 USD , Axsome Therapeutics Inc is Overvalued By 10.41%.
Relative Value
Fair Zone
127.42-151.75
Current Price：167.55
10.41%
Overvalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Axsome Therapeutics Inc (AXSM) has a current Price-to-Book (P/B) ratio of 121.93. Compared to its 3-year average P/B ratio of 47.27 , the current P/B ratio is approximately 157.92% higher. Relative to its 5-year average P/B ratio of 48.69, the current P/B ratio is about 150.43% higher. Axsome Therapeutics Inc (AXSM) has a Forward Free Cash Flow (FCF) yield of approximately -1.13%. Compared to its 3-year average FCF yield of -3.30%, the current FCF yield is approximately -65.90% lower. Relative to its 5-year average FCF yield of -4.56% , the current FCF yield is about -75.32% lower.
P/B
Median3y
47.27
Median5y
48.69
FCF Yield
Median3y
-3.30
Median5y
-4.56
Competitors Valuation Multiple
AI Analysis for AXSM
The average P/S ratio for AXSM competitors is 8.97, providing a benchmark for relative valuation. Axsome Therapeutics Inc Corp (AXSM.O) exhibits a P/S ratio of 10.38, which is 15.71% above the industry average. Given its robust revenue growth of 63.22%, this premium appears sustainable.
Performance Decomposition
AI Analysis for AXSM
1Y
3Y
5Y
Market capitalization of AXSM increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of AXSM in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is AXSM currently overvalued or undervalued?
Axsome Therapeutics Inc (AXSM) is now in the Overvalued zone, suggesting that its current forward PS ratio of 10.38 is considered Overvalued compared with the five-year average of -23.39. The fair price of Axsome Therapeutics Inc (AXSM) is between 127.42 to 151.75 according to relative valuation methord. Compared to the current price of 167.55 USD , Axsome Therapeutics Inc is Overvalued By 10.41% .
What is Axsome Therapeutics Inc (AXSM) fair value?
AXSM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Axsome Therapeutics Inc (AXSM) is between 127.42 to 151.75 according to relative valuation methord.
How does AXSM's valuation metrics compare to the industry average?
The average P/S ratio for AXSM's competitors is 8.97, providing a benchmark for relative valuation. Axsome Therapeutics Inc Corp (AXSM) exhibits a P/S ratio of 10.38, which is 15.71% above the industry average. Given its robust revenue growth of 63.22%, this premium appears sustainable.
What is the current P/B ratio for Axsome Therapeutics Inc (AXSM) as of Jan 10 2026?
As of Jan 10 2026, Axsome Therapeutics Inc (AXSM) has a P/B ratio of 121.93. This indicates that the market values AXSM at 121.93 times its book value.
What is the current FCF Yield for Axsome Therapeutics Inc (AXSM) as of Jan 10 2026?
As of Jan 10 2026, Axsome Therapeutics Inc (AXSM) has a FCF Yield of -1.13%. This means that for every dollar of Axsome Therapeutics Inc’s market capitalization, the company generates -1.13 cents in free cash flow.
What is the current Forward P/E ratio for Axsome Therapeutics Inc (AXSM) as of Jan 10 2026?
As of Jan 10 2026, Axsome Therapeutics Inc (AXSM) has a Forward P/E ratio of -122.77. This means the market is willing to pay $-122.77 for every dollar of Axsome Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Axsome Therapeutics Inc (AXSM) as of Jan 10 2026?
As of Jan 10 2026, Axsome Therapeutics Inc (AXSM) has a Forward P/S ratio of 10.38. This means the market is valuing AXSM at $10.38 for every dollar of expected revenue over the next 12 months.